Business Context and Reporting Period
Company: Profound Medical Corp. (Profound)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Profound is a commercial-stage medical device company developing AI-powered, MRI-guided, incision-free therapies for tissue ablation. Its lead product, the TULSA-PRO system, treats prostate cancer and benign prostatic hyperplasia (BPH). The Sonalleve system treats uterine fibroids, bone metastases, and osteoid osteoma. The company operates globally with a primary focus on the U.S. market.
Key Financial Metrics
| Metric (in USD thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $16,098 | $10,680 |
| Gross Profit | $11,393 | $7,037 |
| Gross Margin | 71% | 66% |
| Operating Expenses | $52,647 | $40,099 |
| Net Loss | $(42,570) | $(27,816) |
| Cash and Cash Equivalents (Year End) | $59,723 | $54,912 |
| Long-Term Debt | $4,499 | $2,924 |
| Accumulated Deficit | $(287,740) | $(245,170) |
Revenue Composition (2025): Recurring non-capital revenue (one-time-use devices/services) was $9.73 million; Capital equipment sales were $6.37 million.
Geographic Revenue (2025): United States (76%), Europe (5%), Asia (19%).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 51% year-over-year, driven by higher recurring revenue and capital sales in the U.S. and overseas.
- Expense Increases: Operating expenses rose 31% to $52.6 million. Research and Development (R&D) increased 21% due to headcount growth and the CAPTAIN clinical trial. Selling, General, and Administrative (SG&A) expenses increased 39% due to sales force expansion and commissions.
- Net Loss Expansion: Net loss increased 53% to $42.6 million, primarily due to higher operating expenses and a reversal of foreign exchange gains seen in 2024.
- Financing Activity: The company raised approximately $40.8 million in net proceeds from a public offering and private placement in December 2025.
- Debt Covenant Compliance: The company experienced a breach of its CIBC Credit Agreement liquidity covenant in August 2025 but obtained a waiver and subsequently amended the agreement in September 2025 to revise the liquidity threshold. The company was in compliance as of December 31, 2025.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to fund operations for at least the next 12 months using existing cash and product sales. The strategy focuses on expanding U.S. commercialization of TULSA-PRO, leveraging new Category 1 CPT codes effective January 1, 2025, which established Medicare reimbursement rates. The company is also advancing the CAPTAIN trial, a randomized controlled trial comparing TULSA to radical prostatectomy, which completed enrollment in 2025.
Key Risks and Contingencies:
- Liquidity and Capital Needs: The company has a history of operating losses and an accumulated deficit of $287.7 million. Continued profitability is not guaranteed, and additional financing may be required.
- Debt Covenants: Future compliance with the CIBC Credit Agreement depends on achieving specific revenue, EBITDA, and unrestricted cash levels. Failure to comply could result in debt acceleration.
- Regulatory and Reimbursement: Commercial success depends on maintaining regulatory clearances (FDA, CE Mark) and securing adequate third-party reimbursement. The company is subject to the New EU Medical Devices Regulation (MDR) transition requirements.
- Internal Controls: A material weakness in internal controls over financial reporting related to revenue recognition (ASC 606) identified in 2024 has been remediated as of December 31, 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $59.7 million cash balance against the projected burn rate and the timeline for achieving profitability.
- Debt Covenant Status: Monitor monthly compliance with the amended CIBC liquidity covenant (unrestricted cash vs. negative EBITDA or $10 million threshold).
- Reimbursement Impact: Assess the actual uptake of the new TULSA CPT codes (55881/55882) and the resulting reimbursement rates from Medicare and private payers.
- CAPTAIN Trial Results: Await the release of data from the CAPTAIN trial comparing TULSA to radical prostatectomy, which is critical for market acceptance and payer coverage.
- EU Regulatory Compliance: Confirm the timeline and costs associated with re-certifying TULSA-PRO and Sonalleve under the New EU MDR before the December 2028 deadline.